Audrey Sternberg

Combination therapies for patients with advanced renal cell carcinoma provides clinicians with new treatment avenues for their patients. To assess which path to go down, Tian Zhang, MD, MHS, and Randy F. Sweis, MD, led virtual discussions on evaluating patients’ risk criteria to determine their proper treatment.

Improvement in overall survival for patients with locally advanced head and neck squamous cell carcinoma was demonstrated with xevinapant plus standard chemoradiotherapy vs matched placebo at the 5-year mark.

Findings from the phase 3 ARIEL4 trial of rucaparib vs chemotherapy in relapsed ovarian cancer with deleterious BRCA1/2 mutations raised questions about optimal sequencing of PARP inhibitors at ESMO 2022.

Sotorasib plus either pembrolizumab or atezolizumab revealed promising efficacy and relatively low rates of hepatotoxicity with a lead-in dosing strategy in patients with KRAS G12C–positive non–small cell lung cancer.

Results of the phase 1 ELAINEI trial will inform the activity of single-agent lasofoxifene in estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations.

Ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer when given before or after surgery.

Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.

Based on a 2022 ASCO Annual Meeting presentation given by Cyrille Touzeau, MD, PhD, the IFM 2018-04 study confirms the efficacy and feasibility of the quadruplet induction regimen Dara-KRd in high-risk, transplant-eligible patients with multiple myeloma.

The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.

Patients with chronic graft-versus-host disease who received a full series of the SARS-CoV-2 vaccine showed varied immune responses, regardless of their baseline characteristics.

Changes like bone marrow fibrosis improvement and variant allele frequency reduction were seen with navitoclax plus ruxolitinib in patients with previously treated myelofibrosis in the REFINE study.

CCR7-positive and CD45RA-positive T cells that expressed CD27 and CD28 appear to be associated with all efficacy metrics, including durability or response, according to an analysis of the ZUMA-7 clinical trial.

According to Primo Nery Lara, Jr, MD, frontline treatment options for metastatic renal cell carcinoma have been improving rapidly.

Findings from the MC1273 and MC1675 trials show that de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

According to updated findings from a cohort of the KRYSTAL-1 trial adagrasib may be active in previously treated KRAS G12C¬–mutant gastrointestinal tumors.

Compared with standard of care, ciltacabtagene autoleucel produces better responses in the setting of heavily pretreated multiple myeloma.

In frail and elderly patients with multiple myeloma who are treated in the relapsed setting, a phase 2 trial shows promise of the daratumumab/ixazomib combination when given without dexamethasone.

Data from a pooled analysis confirm that patients who self-identify as Black or Hispanic can safely benefit from treatment with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.

Imaging mass cytometry at the single-cell level may be a promising response prediction tool for immunotherapy in early triple-negative breast cancer.

Darolutamide was statistically significantly associated with better episodic memory over enzaluamide, according to computerized cognitive assessment in men with metastatic castration-resistant prostate cancer.

Intensifying daratumumab induction therapy may improve responses to therapy in patients with ultra­ high-risk multiple myeloma or primary plasma cell leukemia, according to prospective study results.

The use of daratumumab as maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone was beneficial.

Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.

Intensified induction therapy with daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone followed by bortezomib-augmented autologous stem cell transplant resulting in deep remissions or patients with ultra¬ high-risk multiple myeloma or primary plasma cell leukemia.

Few patients required subsequent anticancer therapies with the combination of lenvatinib (Lenvima) plus everolimus versus sunitinib for advanced renal cell carcinoma

Similar health-reatled quality of life outcomes and disease-related symptom scores were seen between the combination of lenvatinib plus pembrolizumab and sunitinib for the frontline treatment of metastatic renal cell carcinoma.

Continued efficacy is seen with nivolumab and ipilimumab plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer.

For the past 17 years, HPV-related cervical cancer has been declining, however, other tumors related to the virus continue to remain steady.

For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.